Drugs / rDEN2Δ30-7169
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02392325 | Mar 2015 → Jul 2016 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01931176 | Jun 2013 → Dec 2014 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN2Δ30-7169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931176 ↗ |
| Modality | Vaccine | “A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine” NCT01931176 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT01931176 ↗ |